CureVac (NASDAQ:CVAC - Get Free Report)'s share price gapped down before the market opened on Friday . The stock had previously closed at $3.20, but opened at $3.13. CureVac shares last traded at $3.14, with a volume of 99,760 shares traded.
Wall Street Analysts Forecast Growth
Separately, JMP Securities reissued a "market outperform" rating and issued a $16.00 price target on shares of CureVac in a research report on Friday, February 14th.
Check Out Our Latest Stock Report on CVAC
CureVac Stock Up 8.2 %
The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The firm has a market capitalization of $707.46 million, a P/E ratio of 5.75 and a beta of 2.53. The business has a 50 day moving average price of $3.65 and a 200 day moving average price of $3.20.
Institutional Investors Weigh In On CureVac
Hedge funds have recently modified their holdings of the business. Integrated Wealth Concepts LLC acquired a new stake in CureVac in the 3rd quarter worth $35,000. Two Sigma Advisers LP bought a new stake in shares of CureVac in the fourth quarter valued at about $48,000. Jump Financial LLC acquired a new stake in CureVac during the fourth quarter worth about $55,000. D. E. Shaw & Co. Inc. bought a new position in CureVac during the fourth quarter valued at about $66,000. Finally, Barclays PLC acquired a new position in CureVac in the 3rd quarter valued at approximately $67,000. 17.26% of the stock is owned by institutional investors.
About CureVac
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Featured Articles
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
